Overpatented, Overpriced:
Lantus
Special Edition

This case study on the diabetes drug Lantus (insulin glargine)
is the second in a series of in-depth investigations
into the best-selling medicines featured in
I-MAK's Overpatented, Overpriced report.

Download the Report

Join us to stay updated
and help make lifesaving medicines accessible to all